Compare AGO & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGO | IRTC |
|---|---|---|
| Founded | 2003 | 2006 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.9B |
| IPO Year | 2003 | 2016 |
| Metric | AGO | IRTC |
|---|---|---|
| Price | $76.82 | $104.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | $101.67 | ★ $197.92 |
| AVG Volume (30 Days) | 281.6K | ★ 472.6K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.67% | N/A |
| EPS Growth | 49.34 | ★ 61.71 |
| EPS | ★ 1.91 | N/A |
| Revenue | ★ $1,110,000,000.00 | $747,138,000.00 |
| Revenue This Year | $3.06 | $19.60 |
| Revenue Next Year | N/A | $15.94 |
| P/E Ratio | $39.94 | ★ N/A |
| Revenue Growth | ★ 27.29 | 26.24 |
| 52 Week Low | $72.76 | $100.85 |
| 52 Week High | $92.40 | $210.01 |
| Indicator | AGO | IRTC |
|---|---|---|
| Relative Strength Index (RSI) | 49.50 | 39.87 |
| Support Level | $73.47 | $101.75 |
| Resistance Level | $83.65 | $121.88 |
| Average True Range (ATR) | 1.44 | 5.32 |
| MACD | 0.49 | -0.31 |
| Stochastic Oscillator | 71.62 | 22.07 |
Assured Guaranty Ltd. provides credit protection products to the United States and international public finance and structured finance markets and manages assets across collateralized loan obligations as well as opportunity funds and liquid funds that build on its corporate credit, asset-based finance, municipal, and healthcare experience. The company operates in two segments: the Insurance segment and the Asset Management segment. The majority of the revenue earned by the company is from the Insurance segment.
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.